|
| Status |
Public on Oct 29, 2014 |
| Title |
134_PsA_208_CD14-_wk10 |
| Sample type |
RNA |
| |
|
| Source name |
134_PsA_208_CD14-_wk10
|
| Organism |
Homo sapiens |
| Characteristics |
Sex: F
age: 60
cell type: primary cell
cell subtype: CD14-
disease status: diseased
disease: Psoriatic Arthritis
time point: wk10
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Total RNA was isolated from CD14- cells using the RNeasy Mini Kit with DNase digestion on the column (Qiagen, Inc. Valencia, CA, USA) as per the manufacturer’s instructions.
|
| Label |
Biotin
|
| Label protocol |
Target was prepared from 50ng total RNA using NuGEN Ovation V2 kits, followed by NuGEN Encore biotin labeling module using the manufacturer's protocol
|
| |
|
| Hybridization protocol |
All samples were hybridized in parallel to different arrays on the same HT array plate using the manufacturer's protocol. Arrays were washed and stained on an Affymetrix GeneTitan instrument
|
| Scan protocol |
Arrays were scanned using an Affymetrix GeneTitan MC scanner
|
| Data processing |
Affymetrix .cel files were RMA normalized in ArrayStudio from Omicsoft Inc (version 4.1). Differential gene expression was analyzed using paired t-tests and genes were selected based on p-value (affymetrix probe sets with no associated gene annotation were not included)
|
| |
|
| Submission date |
May 07, 2014 |
| Last update date |
Oct 29, 2014 |
| Contact name |
Christopher Ritchlin |
| E-mail(s) |
Christopher_Ritchlin@URMC.Rochester.edu
|
| Phone |
(585) 486-0901
|
| Organization name |
University of Rochester Medical Center
|
| Department |
School of Medicine and Dentistry
|
| Street address |
601 Elmwood Ave, BOX695
|
| City |
Rochester |
| State/province |
NY |
| ZIP/Postal code |
14642 |
| Country |
USA |
| |
|
| Platform ID |
GPL13158 |
| Series (2) |
| GSE57386 |
Gene expression of biopsies, CD14+ and CD14- cells from RA, PsA and PsO patients with Infliximab treatment |
| GSE57405 |
Gene expression of CD14- cells from RA, PsA and PsO patients with Infliximab treatment |
|
